Gene therapy manufacturing partnership to support ‘booming’ market

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/	Yok46233042)
(Image: Getty/ Yok46233042)

Related tags: Gene therapy, CDMO, Manufacturing, Ema, Fda

Axovant has signed a strategic partnership agreement with the CDMO Yposkesi to support its growing gene therapy pipeline.

Through the agreement, Yposkesi, a contract development and manufacturing organization (CDMO) specializing in viral vector manufacturing, will provide Axovant Sciences access to current good manufacturing processes (cGMP) grade facilities for Adeno-Associated​ Virus (AAV) production.

Axovant will receive dedicated suite space and access to manufacturing resources for its AAV-based gene therapy programs through development and commercialization.

Alain Lamproye, CEO of Yposkesi, told us “flexible and quick access to manufacturing capacity is key in the development of early stage clinical candidates, and especially for viral vectors where a global shortage of capacity has been observed.”

Lamproye said the gene therapy manufacturing market is “booming,”​ and will continue to grow at rates ranging from 15-20%.

“The recent clinical successes in the treatment of neuromuscular diseases, as well as the advent of CAR-T cells, are all indicators triggering demand for large-scale manufacturing capacities,”​ he explained.

Additionally, the two companies will work together to establish practices in process development, technology transfer, manufacturing scale-up, quality control and assurance.

Yposkesi will expand its capacity in 2019 to support commercial production following this agreement. The company said it will increase its global footprint by 2021 through a 100,000 square-foot facility equipped with several 1,000L bioreactors.

The manufacturing processes provided through this partnership comply with both European Medicines Agency (EMA) guidelines as well as US Food and Drug Administration (FDA) requirements for Phase I-III clinical trial supplies.

Related news

Related products

show more

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Discover Fermion’s new API unit 4 in Hanko

Discover Fermion’s new API unit 4 in Hanko

Recorded the 04-Sep-2018 | Webinar

Join this webinar to learn more about Fermion’s new manufacturing unit 4 at the Hanko site. This webinar will provide virtual tour to our new state of...

Related suppliers

Follow us

Products

View more

Webinars